Updates in recent clinical guidelines have led to a change in the management of perioperative anticoagulation for patients on oral anticoagulant therapy. No standardized bridging consensus exists in the literature. The necessity for bridging therapy is determined based on careful consideration of the thrombosis risk versus the bleeding risk of the procedure. Risk stratification will aid the decision to bridge or not to bridge. Patients are bridged with agents with appropriate kinetics to allow for their elimination prior to the time of the procedure in order to decrease the risk of hemorrhage during invasive procedures. This intent of this article is to discuss perioperative bridging therapy and provide a practical guide for the clinician.
DouketisJDBergerPBDunnAS. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 suppl):299–339.
2.
MannucciCDouketisJD. The management of patients who require temporary reversal of vitamin K antagonists for surgery: a practical guide for clinicians. Intern Emerg Med. 2006;1(2):96–104.
3.
GageBFWatermanADShannonW. Validation of clinical classification schemes for predicting stroke. JAMA. 2001;285(22):2864–2870.
4.
KaplanRCTirschwellDLLongstrethWT. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology. 2005;65(6):835–842.
5.
BaudetEMPeulVMcBirdeJT. Long-term results of valve replacement with the St. Jude medical prosthesis. J Thorac Cardiovasc Surg. 1995;109(5):858–870.
6.
SpyropoulosAC. Perioperative bridging therapy for the at-risk patient on chronic anticoagulation. Dis Mon. 2005;51(2-3):183–193.
7.
DouketisJDGuCSSchulmanS. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2007;147(11):766–774.
8.
SchulmanSKearonC. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694.
9.
DunnASTurpieAG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003;163(8):901–908.
10.
GarciaDAReganSHenaultLE. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168(1):63–69.
11.
DouketisJDJohnsonJATurpieAG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164(12):1319–1326.
12.
SpyropoulosACTurpieAGSpandorferJ. Clinical outcomes with unfractionated heparin of low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006;4(6):1246–1252.
13.
SpyropoulosACTurpieAGDunnAS. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN registry). Am J Cardiol. 2008;102(7):883–889.
14.
PengoVCucchiniUDenasG. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation. 2009;119(22):2920–2927.
DunnASSpyropoulosATurpieAG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5(11):2211–2218.
17.
WysokinskiWEMcBaneRDDanielsPR. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc. 2008;83(6):639–645.
18.
BajkinBVPopovicSLSelakovicSD. Randomized, prospective trial comparing bridging therapy using low- molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth. J Oral Maxillofac Surg. 2009;67(5):990–995.
19.
Sindet-PedersenSRamstromGBernvilS. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med. 1989;320(13):840–843.
20.
PerryDJNoakesJCHelliwellPS. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J. 2007;203(7):389–393.
21.
NutescuEASpinlerSAWittkowskyA. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43(6):1064–1083.
22.
ScholtenDJHoedemaRMScholtenSE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002;12(1):19–24.
23.
MaheIAghassarianMDrouetL. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost. 2007;97(4):581–586.
24.
TincaniEMannuciCCasolariB. Safety of dalteparin in prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006;91(7):976–979.
25.
SanderinkGJGuimartCGOzouxML. Pharmacokinetics and Pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002;105(3):225–231.
26.
MaheIGouin-ThebaultIDrouetL. Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging. 2007;24(1):63–71.
27.
BeckerRCSpencerFAGibsonM. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143(5):753–759.
28.
ShprecherARCheng-LaiAMadsenEM. Peak antifactor Xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy. 2005;25(6):817–822.
29.
PautusEGouinKBellottO. Safety profile of tinzaparin administered once daily at standard curative dose in two hundred very elderly patients. Drug Safety. 2002;25(10):725–733.
30.
SigueretVPautusEFevrierM. Elderly patients treated with tinzaparin (Innohep) administrated once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84(5):800–804.
31.
WhiteHDBraunwaldEMurphySA. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J. 2007;28(9):1066–1071.
32.
PERIOP 2—A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin. http://clinicaltrials.gov/ct2/show/study/NCT00432796. Accessed July 27, 2009.
